In the 2025 Payer Oncology Trend Report, we analyze how health plans and PBMs are navigating the shifting landscape of branded cancer drug management. To deepen our findings, we spoke with industry experts Michael Kolodziej, MD, and Ira Klein, Vice President, Medical Affairs & Payer Relations at Tempus, who shared their perspectives on the data, key trends, and what these insights mean for manufacturers moving forward.

In this episode, MAI team members share thought-provoking quotes and insights gathered from conversations this year with key decision makers involved with IDNs, Community Oncology Practices, Payers & Pathways.

In part 3 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—conclude their conversation on oncology practice economics, discussing emerging models for success (e.g., utilization of advanced therapies) and manufacturer implications.

In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—continue their exploration of oncology practice economics, focusing on practices’ operational realities.

In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider. and oncology strategist—explore the current state of oncology practice economics.

 In part 2 of this 2-part podcast series, HMP MAI Director of Payer Insights Chris Van Denburg and special guest Tina Valbh – pharmacist and oncology patient – continue their exploration of oncology patient support services programs, with several key pieces of advice for biopharmaceutical companies.

In part 1 of this 2-part podcast series, HMP MAI Director of Payer Insights Chris Van Denburg and special guest Tina Valbh – pharmacist and oncology patient – explore her experiences with and advice for oncology patient support services programs, emphasizing those provided by biopharmaceutical companies.

HMP MAI Director of Payer Insights Chris Van Denburg and special guest and notable specialist Carole Tremonti, RN, MBA, investigate key insights about what clinical decision support systems—and AI—are and are NOT, what we can rely on them for currently, and how biopharmaceutical companies with oncology products can prepare for success related to these advances. 

In this episode, you will hear from the research leads for each of our key customer segments about 3 notable quotes they heard from conversations this year with providers, payers, and administrators in the oncology sector.

In this episode, we provide highlights on key insights from our 2023 Community Oncology Annual Trend Report, including why it's important for pharma companies to tailor their approach with community oncology groups based on what archetype they fall under. 

Part 2 of HMP MAI’s podcast on value-based cancer care looking at how prevalent VBC is in primary and cancer care, private payer VBC activity specifically in oncology, and ideas about how biopharmaceutical manufacturers might adjust to shifting customer interests because of VBC.

Part 1 of HMP MAI’s podcast on value-based cancer care looking at traditional provider priorities, how VBC attempts to adjust those priorities, and who some of the largest VBC players are in primary and cancer care.

In this episode, we look back on the most critical topics covered by our research this year: the Inflation Reduction Act of 2022, value-based care from a payer perspective, and evolving provider revenue and survival strategies.

In this episode, we analyze the next rendition of CMMI's Oncology Care Model -  Enhancing Oncology Model - and what it means for oncology market access

Our second podcast for 2022 focuses on trends in vertical payer integration and reviews our concepts of “Consolidation 2.0” and “Consolidation 2.1” in which the healthcare conglomerates first begin to employ physicians, and then leverage technology to interact with patients virtually.  In this podcast we speak with Dr. Michael Kolodziej. Dr. Kolodziej’s experience includes New York Oncology Hematology, Aetna, Flatiron, and now ADVI Health, where he is VP and Chief Innovation Officer. Part 2 of 2.

Our first podcast for 2022 focuses on trends in vertical payer integration and reviews our concepts of “Consolidation 2.0” and “Consolidation 2.1” in which the healthcare conglomerates first begin to employ physicians, and then leverage technology to interact with patients virtually. In this podcast we speak with Dr. Michael Kolodziej. Dr. Kolodziej’s experience includes New York Oncology Hematology, Aetna, Flatiron, and now ADVI Health, where he is VP and Chief Innovation Officer. Part 1 of 2.

In this episode, we explore the practice of "white bagging" - or payer directed IDN drug dispensing - and how an IDN cancer center changes internal processes to accommodate the increased operational burden. Manufacturer awareness of the practice provides insights into future opportunities for supporting their IDN clients.

In the latest episode of our Insight to Access podcast series, we sit down with Julie Kennerly-Shah, Assistant Director of Pharmacy at the James Cancer Center, to get her perspective and personal experience on: Key considerations in the evaluation of providing home infusion services Benefits and challenges of shifting infusions to the home setting Why some systems are piloting these services while others are waiting on the sidelines

We highlight key learning from our recent research initiative into oncology drug management and clinical support with the top EHR systems in IDN and community oncology settings.

Cindy Chen and Daniel Levis of Proximity Health's data analytics team sit down to discuss the increasing share of provider owned specialty pharmacy including barriers to entry and incentives for adoption.